<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599816</url>
  </required_header>
  <id_info>
    <org_study_id>annie-panagiotis</org_study_id>
    <nct_id>NCT04599816</nct_id>
  </id_info>
  <brief_title>Levosimendan Administration in Pulmonary Hypertension</brief_title>
  <acronym>Levosim-PH</acronym>
  <official_title>Levosimendan Administration in High Risk Cardiac Surgery Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aretaieion University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aretaieion University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine the pharmacokinetics and pharmacodynamic properties of&#xD;
      Levosimendan in cardiac surgery patients with pulmonary hypertension and impaired right&#xD;
      ventricular function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PH) is a pathophysiological disorder hemodynamically characterized by&#xD;
      increased pulmonary vascular resistance and pressure. This can lead to right ventricle&#xD;
      pressure overload and failure which is worsened by cardiopulmonary bypass (CPB) and&#xD;
      extracorporeal circulation and is accompanied by high rates of morbidity and mortality in&#xD;
      cardiac surgery patients. Pharmacological agents used to decrease pulmonary vascular&#xD;
      resistance and right ventricle afterload are prostaglandins, iloprost, milrinone, nitric&#xD;
      oxide (NO) and recently Levosimendan. These agents can be administered intravenously or via&#xD;
      inhalation.&#xD;
&#xD;
      In this study, Levosimendan will be administered in patients with pulmonary hypertension&#xD;
      undergoing cardiac surgery. The aim of the study is to examine the pharmacokinetics and&#xD;
      pharmacodynamic properties of Levosimendan in cardiac surgery patients with pulmonary&#xD;
      hypertension and impaired right ventricular function. The drug will be administered in&#xD;
      different doses to define the dose at which Levosimendan administration reduces pulmonary&#xD;
      vascular resistance and pressure without causing significant reduction of systemic vascular&#xD;
      resistance and pressure. The anti-inflammatory effect of the perioperative use of&#xD;
      Levosimendan in cardiac surgery will also be studied.&#xD;
&#xD;
      In this setting, 45 patients with PH caused by left sided heart disease, will be assigned&#xD;
      into three groups:&#xD;
&#xD;
      GROUP A: Administration of Levosimendan at a dosage of 3mcg/kg after anesthesia induction.&#xD;
&#xD;
      GROUP B: Administration of Levosimendan at a dosage of 6mcg/kg after anesthesia induction.&#xD;
&#xD;
      GROUP C: Administration of Levosimendan at a dosage of 12mcg/kg after anesthesia induction.&#xD;
&#xD;
      Before and after the administration of the drug, heart function will be evaluated by&#xD;
      hemodynamic measurements obtained by the Swan-Ganz catheter. These parameters will be heart&#xD;
      rate (HR), blood pressure (BP), mean pulmonary arterial pressure (MPAP), central venous&#xD;
      pressure (CVP), cardiac output (CO), pulmonary capillary wedge pressure (PCWP), cardiac index&#xD;
      (CI), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR). Transthoracic&#xD;
      echocardiography (TTE) and transoesophageal echocardiography (TOE) will also be used. The&#xD;
      anti-inflammatory action of Levosimendan will also be evaluated by interleukin-6 (IL-6)&#xD;
      measurements.&#xD;
&#xD;
      This study will lead to conclusions regarding the effectiveness of Levosimendan&#xD;
      administration in the treatment of right heart failure and PH in cardiac surgery patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2020</start_date>
  <completion_date type="Anticipated">October 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in mean pulmonary arterial pressure (MPAP)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>a Swan-Ganz catheter will be used for hemodynamic measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in pulmonary vascular resistance (PVR)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>a Swan-Ganz catheter will be used for hemodynamic measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in mean arterial pressure (MAP)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>a Swan-Ganz catheter will be used for hemodynamic measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in systemic vascular resistance (SVR)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>a Swan-Ganz catheter will be used for hemodynamic measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in pulmonary capillary wedge pressure (PCWP)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>a Swan-Ganz catheter will be used for hemodynamic measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in cardiac output (CO)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>a Swan-Ganz catheter will be used for hemodynamic measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in tricuspid annular plane systolic excursion (TAPSE)</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery, 2 hours after Intensive Care Unit (ICU) admission and 80 hours after levosimendan administration</time_frame>
    <description>transthoracic and transesophageal echocardiography will be used for echocardiographic measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in fractional area change</measure>
    <time_frame>20 minutes after levosimendan administration, at the end of surgery, 2 hours after Intensive Care Unit (ICU) admission and 80 hours after levosimendan administration</time_frame>
    <description>transthoracic and transesophageal echocardiography will be used for echocardiographic measurements</description>
  </secondary_outcome>
  <other_outcome>
    <measure>change from baseline in blood levels of levosimendan</measure>
    <time_frame>20 minutes, 6 hours, 12 hours, 24 hours and 80 hours after administration</time_frame>
    <description>blood levels will be measured with liquid chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>change from baseline in blood levels of interleukin-6 (IL-6)</measure>
    <time_frame>end of surgery, 6 hours, 12 hours and 24 hours after Intensive Care Unit (ICU) admission</time_frame>
    <description>blood levels will be measured with the enzyme linked immunosorbent assay (ELISA)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Cardiac Failure</condition>
  <condition>Pulmonary Vascular Resistance Abnormality</condition>
  <arm_group>
    <arm_group_label>levosimendan administration at a dose of 3 mcg/kg after anesthesia induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levosimendan administration at a dose of 6 mcg/kg after anesthesia induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levosimendan administration at a dose of 12 mcg/kg after anesthesia induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan at a dose of 3 mcg/kg</intervention_name>
    <description>levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction</description>
    <arm_group_label>levosimendan administration at a dose of 3 mcg/kg after anesthesia induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan at a dose of 6 mcg/kg</intervention_name>
    <description>levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction</description>
    <arm_group_label>levosimendan administration at a dose of 6 mcg/kg after anesthesia induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan at a dose of 12 mcg/kg</intervention_name>
    <description>levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction</description>
    <arm_group_label>levosimendan administration at a dose of 12 mcg/kg after anesthesia induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with pulmonary hypertension due to left ventricular dysfunction based on&#xD;
             echocardiographic diagnosis preoperatively&#xD;
&#xD;
          -  elective cardiac surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary pulmonary hypertension&#xD;
&#xD;
          -  thromboembolic disease&#xD;
&#xD;
          -  chronic obstructive pulmonary disease&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  redo surgery&#xD;
&#xD;
          -  inability to consent to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kassiani Theodoraki, PhD, DESA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aretaieion University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kassiani Theodoraki, PhD, DESA</last_name>
    <phone>+306974634162</phone>
    <email>ktheodoraki@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Center</name>
      <address>
        <city>Athens</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theophani Antoniou, MD, PhD</last_name>
      <email>antoniou_fani@yahoo.gr</email>
    </contact>
    <contact_backup>
      <last_name>Panagiotis Ftikos, MD</last_name>
      <email>pftikos@yahoo.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrakis P, Antoniou T. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth. 2002 Nov;49(9):963-7.</citation>
    <PMID>12419726</PMID>
  </reference>
  <reference>
    <citation>Theodoraki K, Thanopoulos A, Rellia P, Leontiadis E, Zarkalis D, Perreas K, Antoniou T. A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension. Heart Vessels. 2017 Dec;32(12):1488-1497. doi: 10.1007/s00380-017-1023-2. Epub 2017 Jul 17.</citation>
    <PMID>28717881</PMID>
  </reference>
  <reference>
    <citation>Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. Anesth Analg. 2009 Feb;108(2):422-33. doi: 10.1213/ane.0b013e31818d8b92. Review.</citation>
    <PMID>19151265</PMID>
  </reference>
  <reference>
    <citation>Hansen MS, Andersen A, Nielsen-Kudsk JE. Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ. 2018 Jul-Sep;8(3):2045894018790905. doi: 10.1177/2045894018790905. Epub 2018 Jul 6.</citation>
    <PMID>29979110</PMID>
  </reference>
  <reference>
    <citation>Boost KA, Hoegl S, Dolfen A, Czerwonka H, Scheiermann P, Zwissler B, Hofstetter C. Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury. Crit Care Med. 2008 Jun;36(6):1873-9. doi: 10.1097/CCM.0b013e3181743e63.</citation>
    <PMID>18496375</PMID>
  </reference>
  <reference>
    <citation>Kundra TS, Nagaraja PS, Bharathi KS, Kaur P, Manjunatha N. Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement. Ann Card Anaesth. 2018 Jul-Sep;21(3):328-332. doi: 10.4103/aca.ACA_19_18.</citation>
    <PMID>30052230</PMID>
  </reference>
  <reference>
    <citation>Elhassan A, Essandoh M. Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension. J Cardiothorac Vasc Anesth. 2019 Apr;33(4):1169-1170. doi: 10.1053/j.jvca.2018.11.039. Epub 2018 Nov 28.</citation>
    <PMID>30612930</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Gage EM, Ji QC, El-Shourbagy TA. A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography/tandem mass spectrometric detection. Rapid Commun Mass Spectrom. 2007;21(14):2169-76.</citation>
    <PMID>17631672</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aretaieion University Hospital</investigator_affiliation>
    <investigator_full_name>Dr Kassiani Theodoraki</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>pulmonary vascular resistance</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>vasodilators</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

